Skip to main
SNN
SNN logo

SNN Stock Forecast & Price Target

SNN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

Smith & Nephew's financial outlook remains positive, bolstered by a strong underlying revenue growth of 5.3%, excluding challenges in China, and expectations for continued strength in U.S. sports medicine and advanced wound therapy segments. Key growth drivers include a significant 23.9% increase in other reconstruction revenues, spurred by record CORI placements, along with a projected trading profit margin between 19.0% and 20.0% for 2025, suggesting operational efficiencies and cost improvements. Furthermore, the company anticipates a stronger second half of the year, supported by sustained demand in its orthopedic products and an overall group revenue growth of 4.7%.

Bears say

Smith & Nephew faces a challenging outlook due to weaker revenue guidance for FY25, influenced by factors such as a reduced number of selling days, distributor inventory adjustments in China, and anticipated negative impacts from Value-Based Pricing (VBP) initiatives, particularly in the Advanced Wound Therapy segment. The company's return on invested capital (ROIC) within the orthopedic segment is a concern, as it remains significantly lower than its other business units, which could hinder profitability. Additionally, ongoing risks related to political stability and regulatory changes in emerging markets, along with potential decreases in reimbursement rates in the evolving U.S. healthcare landscape, further contribute to the negative outlook on the company's financial performance.

SNN has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Smith & Nephew and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Smith & Nephew (SNN) Forecast

Analysts have given SNN a Hold based on their latest research and market trends.

According to 4 analysts, SNN has a Hold consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Smith & Nephew (SNN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.